Note: Claims are shown in the official language in which they were submitted.
-72-
CLAIMS:
1. Use of an anti-human tumor necrosis factor-.alpha. monoclonal
antibody or a human tumor necrosis factor-.alpha. binding Fab
fragment thereof for the manufacture of a medicament for
performing adjunctive therapy with a medicament comprising
methotrexate on an individual suffering from rheumatoid
arthritis whose active disease is incompletely controlled
despite already receiving methotrexate, to reduce or
eliminate signs and symptoms associated with the rheumatoid
arthritis, wherein the anti-human tumor necrosis factor-.alpha.
antibody or human tumor necrosis factor-a binding Fab
fragment (a) binds to an epitope on human tumor necrosis
factor-.alpha., and (b) inhibits binding of human tumor necrosis
factor-.alpha. to human tumor necrosis factor-.alpha. cell surface
receptors.
2. Use of an anti-human tumor necrosis factor-.alpha. monoclonal
antibody or a human tumor necrosis factor-.alpha. binding Fab
fragment thereof for the manufacture of a medicament for
performing adjunctive therapy with a medicament comprising
methotrexate on an individual suffering from rheumatoid
arthritis who still has active disease despite prior therapy
with methotrexate and who is already being treated with
methotrexate, to reduce or eliminate signs and symptoms
associated with the rheumatoid arthritis, wherein the anti-
human tumor necrosis factor-.alpha. antibody or human tumor
necrosis factor-.alpha. binding Fab fragment inhibits binding of
human tumor necrosis factor-.alpha. to human tumor necrosis factor-
a cell surface receptors.
3. The use of claim 1 or 2, wherein the anti-tumor necrosis
-73-
factor-.alpha. antibody is a chimeric antibody.
4. The use of claim 3, wherein the chimeric antibody binds
to the epitope of human tumor necrosis factor-.alpha. recognized by
a cA2 antibody.
5. The use of any one of claims 1 to 4, wherein the
antibody is infliximab.
6. The use of any one of claims 1 to 5, wherein the anti-
human tumor necrosis factor-.alpha. antibody-containing medicament
is formulated for administration via infusion.
7. The use of any one of claims 1 to 6, wherein the anti-
human tumor necrosis factor-.alpha. antibody or a human tumor
necrosis factor-.alpha. binding Fab fragment-containing medicament
is formulated for administration at an interval of one day to
thirty weeks.
8. The use according to any one of claims 1 to 7, wherein
the methotrexate-containing medicament is formulated for
administration in the form of a series of low doses separated
by intervals of days or weeks.
9. The use according to any one of claims 1 to 8, wherein
the anti-human tumor necrosis factor-a antibody or human
tumor necrosis factor-.alpha. binding Fab fragment-containing
medicament is formulated for administration multiple times,
spaced at an interval of weeks.
10. The use of any one of claims 1 to 9, wherein (a) the
anti-human tumor necrosis factor-.alpha. antibody or human tumor
-74-
necrosis factor-.alpha. binding Fab fragment-containing medicament
is formulated for administration multiple times, spaced at an
interval of weeks, and (b) the methotrexate-containing
medicament is formulated for administration at intervals of
weeks.
11. The use of any one of claims 1 to 10, wherein the
methotrexate-containing medicament contains 10 milligrams of
methotrexate.
12. The use of any one of claims 1 to 10, wherein (a) the
methotrexate-containing medicament contains 7.5mg of
methotrexate and is formulated for administration weekly
beginning at week 0, and (b) the anti-TNF.alpha. antibody is
infliximab and the anti-human tumor necrosis factor-.alpha.
antibody or human tumor necrosis factor-.alpha. binding Fab
fragment-containing medicament is formulated for
administration by infusion at weeks 0, 2, 6, 10 and 14.
13. The use according to any one of claims 1 to 12, wherein
the anti-tumor necrosis factor .alpha. antibody is a chimeric
monoclonal antibody, and the anti-human tumor necrosis
factor-.alpha. antibody or human tumor necrosis factor-.alpha. binding
Fab fragment-containing medicament is formulated for
administration as multiple infusions.
14. The use according to any one of claims 1 to 11, wherein
(a) the anti- tumor necrosis factor a antibody is infliximab,
(b) the anti-human tumor necrosis factor-.alpha. antibody or human
tumor necrosis factor-.alpha. binding Fab fragment-containing
medicament is formulated for administration in combination
with the methotrexate-containing medicament as a single
-75-
infusion of anti-TNF antibody, and (c) the methotrexate-
containing medicament contains 10 milligrams of methotrexate.
15. The use according to any one of claims 1 to 11, wherein
(a) the anti- tumor necrosis factor a antibody is
infliximab, (b) the anti-human tumor necrosis factor-.alpha.
antibody or human tumor necrosis factor-.alpha. binding Fab
fragment-containing medicament is formulated for
administration as a repeated infusion, and (c) the
methotrexate-containing medicament contains 10 milligrams of
methotrexate.
16. The use according to any one of claims 1 to 15, wherein
the anti-human tumor necrosis factor-.alpha. antibody or human
tumor necrosis factor-.alpha. binding Fab fragment is infliximab.
17. A pharmaceutical composition comprising an anti-human
tumor necrosis factor-.alpha. monoclonal antibody or a human tumor
necrosis factor-.alpha. binding Fab fragment thereof, in admixture
with a pharmaceutically acceptable diluent or carrier, for
use in performing adjunctive therapy with a medicament
comprising methotrexate on an individual suffering from
rheumatoid arthritis whose active disease is incompletely
controlled despite already receiving methotrexate, to reduce
or eliminate signs and symptoms associated with the
rheumatoid arthritis, wherein the anti-human tumor necrosis
factor-.alpha. antibody or human tumor necrosis factor-.alpha. binding
Fab fragment (a) binds to an epitope on human tumor necrosis
factor-.alpha., and (b) inhibits binding of human tumor necrosis
factor-.alpha. to human tumor necrosis factor-.alpha. cell surface
receptors.
-76-
18. A pharmaceutical composition comprising an anti-human
tumor necrosis factor-.alpha. monoclonal antibody or a human tumor
necrosis factor-.alpha. binding Fab fragment thereof, in admixture
with a pharmaceutically acceptable diluent or carrier, for
use in performing adjunctive therapy with a medicament
comprising methotrexate on an individual suffering from
rheumatoid arthritis who still has active disease despite
prior therapy with methotrexate and who is already being
treated with methotrexate, to reduce or eliminate signs and
symptoms associated with the rheumatoid arthritis, wherein
the anti-human tumor necrosis factor-.alpha. antibody or human
tumor necrosis factor-.alpha. binding Fab fragment inhibits binding
of human tumor necrosis factor-.alpha. to human tumor necrosis
factor-.alpha. cell surface receptors.
19. The pharmaceutical composition of claim 16 or 17,
wherein the anti-tumor necrosis factor-.alpha. antibody is a
chimeric antibody.
20. The pharmaceutical composition of claim 19, wherein the
chimeric antibody binds to the epitope of human tumor
necrosis factor-.alpha. recognized by a cA2 antibody.
21. The pharmaceutical composition of any one of claims 17
to 20, wherein the antibody is infliximab.
22. The pharmaceutical composition of any one of claims 17
to 21, wherein the anti-human tumor necrosis factor-.alpha.
antibody or human tumor necrosis factor-.alpha. binding Fab
fragment-containing medicament is formulated for
administration via infusion.
-77-
23. The pharmaceutical composition of any one of claims 17
to 22, wherein the anti-human tumor necrosis factor-.alpha.
antibody or human tumor necrosis factor-.alpha. binding Fab
fragment-containing medicament is formulated for
administration at an interval of one day to thirty weeks.
24. The pharmaceutical composition of any one of claims 17
to 23, wherein the methotrexate-containing medicament is
formulated for administration in the form of a series of low
doses separated by intervals of days or weeks.
25. The pharmaceutical composition of any one of claims 17
to 24, wherein the anti-human tumor necrosis factor-.alpha.
antibody or human tumor necrosis factor-.alpha. binding Fab
fragment-containing medicament is formulated for
administration multiple times, spaced at an interval of
weeks.
26. The pharmaceutical composition of any one of claims 17
to 25, wherein (a) the anti-human tumor necrosis factor-.alpha.
antibody or human tumor necrosis factor-.alpha. binding Fab
fragment-containing medicament is formulated for
administration multiple times, spaced at an interval of weeks
and (b) the methotrexate-containing medicament is formulated
for administration at intervals of weeks.
27. The pharmaceutical composition of any one of claims 17
to 26, wherein the methotrexate-containing medicament
contains 10 milligrams of methotrexate.
28. The pharmaceutical composition of any one of claims 17
to 26, wherein (a) the methotrexate-containing medicament
-78-
contains 7.5 mg of methotrexate and is formulated for
administration weekly beginning at week 0, and (b) the anti-
human tumor necrosis factor-.alpha. antibody is infliximab and the
anti-human tumor necrosis factor-.alpha. antibody or human tumor
necrosis factor-.alpha. binding Fab fragment-containing medicament
is formulated for administration by infusion at weeks 0, 2,
6, 10 and 14.
29. The pharmaceutical composition of any one of claims 17
to 28, wherein the anti- tumor necrosis factor .alpha. antibody is
a chimeric monoclonal antibody, and the anti-human tumor
necrosis factor-.alpha. antibody or human tumor necrosis factor-.alpha.
binding Fab fragment-containing medicament is formulated for
administration as multiple infusions.
30. The pharmaceutical composition of any one of claims 17
to 27, wherein (a) the anti- tumor necrosis factor a antibody
is infliximab, (b) the anti-human tumor necrosis factor-.alpha.
antibody or human tumor necrosis factor-.alpha. binding Fab
fragment-containing medicament is formulated for
administration in combination with the methotrexate-
containing medicament as a single infusion, and (c) the
methotrexate-containing medicament contains 10 milligrams of
methotrexate.
31. The pharmaceutical composition of any one of claims 17
to 27, wherein (a) the anti- tumor necrosis factor .alpha. antibody
is infliximab, (b) the anti-human tumor necrosis factor-.alpha.
antibody or human tumor necrosis factor-.alpha. binding Fab
fragment-containing medicament is formulated for
administration as a repeated infusion, and (c) the
methotrexate-containing medicament contains 10 milligrams of
-79-
methotrexate.
32. The pharmaceutical composition of any one of claims 17
to 28, wherein the anti-human tumor necrosis factor-.alpha.
antibody or human tumor necrosis factor-.alpha. binding Fab
fragment-containing medicament is formulated for
administration as a dosage form containing from about 0.1
milligram to about 500 milligrams of the anti anti-human
tumor necrosis factor-.alpha. antibody or human tumor necrosis
factor-.alpha. binding Fab fragment.
33. The pharmaceutical composition of any one of claims 17
to 28, wherein the anti-human tumor necrosis factor-.alpha.
antibody is infliximab and the anti-human tumor necrosis
factor-.alpha. antibody or human tumor necrosis factor-.alpha. binding
Fab fragment-containing medicament is formulated for
administration as a dosage form containing from about 0.1
milligram to about 500 milligrams of infliximab.
34. The pharmaceutical composition of any one of claims 17
to 33, wherein the anti-human tumor necrosis factor-.alpha.
antibody or human tumor necrosis factor-.alpha. binding Fab
fragment is infliximab.
35. The pharmaceutical composition of any one of claims 17
to 20, wherein the antibody is a humanized antibody.
36. The use of any one of claims 1 to 4, wherein the
antibody is a humanized antibody.
37. The use of any one of claims 1 to 4, wherein the
antibody is a recombinant antibody.
-80-
38. The pharmaceutical composition of any one of claims 17 to
20, wherein the antibody is a recombinant antibody.
39. Use of an anti-human tumor necrosis factor-.alpha. monoclonal
antibody for the manufacture of a medicament for performing
adjunctive therapy with methotrexate for the reduction in
signs and symptoms, inhibition of the progression of
structural damage, or improving physical function in an adult
patient with moderately to severely active rheumatoid
arthritis whose active disease is incompletely controlled
despite already receiving methotrexate, wherein the anti-
human tumor necrosis factor-.alpha. antibody (a) binds to an
epitope on human tumor necrosis factor-.alpha., and (b) inhibits
binding of human tumor necrosis factor-.alpha. to human tumor
necrosis factor-.alpha. cell surface receptors.
40. Use of an anti-human tumor necrosis factor-.alpha. monoclonal
antibody for the manufacture of a medicament for performing
adjunctive therapy with methotrexate for the reduction in
signs and symptoms, inhibition of the progression of
structural damage, or improving physical function in an adult
patient with moderately to severely active rheumatoid
arthritis who still has active disease despite prior therapy
with methotrexate and who is already being treated with
methotrexate, wherein the anti-human tumor necrosis factor-.alpha.
antibody inhibits binding of human tumor necrosis factor-.alpha. to
human tumor necrosis factor-.alpha. cell surface receptors.
41. A pharmaceutical composition comprising an anti-human
tumor necrosis factor-.alpha. monoclonal antibody, in admixture
with a pharmaceutically acceptable diluent or carrier, for
-81-
use in performing adjunctive therapy with methotrexate for
the reduction in signs and symptoms, inhibition of the
progression of structural damage, or improving physical
function in an adult patient with moderately to severely
active rheumatoid arthritis whose active disease is
incompletely controlled despite already receiving
methotrexate, wherein the anti-human tumor necrosis factor-.alpha.
antibody (a) binds to an epitope on human tumor necrosis
factor-.alpha., and (b) inhibits binding of human tumor necrosis
factor-.alpha. to human tumor necrosis factor-.alpha. cell surface
receptors.
42. A pharmaceutical composition comprising an anti-human
tumor necrosis factor-.alpha. monoclonal antibody, in admixture
with a pharmaceutically acceptable diluent or carrier, for
use in performing adjunctive therapy with methotrexate for
the reduction in signs and symptoms, inhibition of the
progression of structural damage, or improving physical
function in an adult patient with moderately to severely
active rheumatoid arthritis who still has active disease
despite prior therapy with methotrexate and who is already
being treated with methotrexate, wherein the anti-human tumor
necrosis factor-.alpha. antibody inhibits binding of human tumor
necrosis factor-.alpha. to human tumor necrosis factor-.alpha. cell
surface receptors.
